The 7th Annual California ALS research network and PAC10 meeting

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingThe 7th Annual California ALS research network and PAC10 meeting

HD-CARE INAUGURAL SYMPOSIUM

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingHD-CARE INAUGURAL SYMPOSIUM

California ALS Research Summit 2016

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingCalifornia ALS Research Summit 2016

Phase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS)

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingPhase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS)

A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingA Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis

A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingA Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease

Clinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingClinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome

Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

• Post author:
• Post published:October 1, 2026
• Post category:

Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease

• Post author:
• Post published:October 1, 2026
• Post category:

Therapeutic Candidate or Device Autologous stem cell-derived dopaminergic neuron replacement therapy. Indication Parkinson’s disease Therapeutic Mechanism The investigational cell therapy product is being studied as an autologous neuron replacement for…

Continue ReadingPhase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease